Alemtuzumab disorders

Nine of 27 patients with multiple sclerosis developed antibodies against the thyrotropin receptor and carbima-zole-responsive autoimmune hyperthyroidism after a 5-day pulse of alemtuzumab, a finding that was not reported in patients treated for other disorders (18). 

Alemtuzumab [Campath] Chronic lymphocytic leukemia Blood disorders [anemia, leukopenia, neutropenia, thrombocytopenia] chest pain, dyspnea infection nausea... 

Thursky KA et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. British Journal of Haematology 2006 132 3-12. 

Tumorigenidty When a strategy of preemptive rituximab therapy is used, alemtuzumab-based T cell-depleted allogeneic hemopoietic stem-cell transplantation is associated with a low (<1%) risk of posttransplant tymphoproUferative disorder [74 ], but it has been reported to occur [75 ]. 

Tumorigenidty Lymphoproliferative disorders have been reported after pancreas transplantation following alemtuzumab induction in 100 patients [146. Epstein-Barr virus-positive immunodeficiency lymphoma after therapy with alemtuzumab... 

In a study of alemtuzumab for the treatment of acute rejection in 15 kidney transplant recipients, the rates of malignancies in alemtuzumab-treated patients were not increased during 12 years follow-up in particular, no patients treated with alemtuzumab for acute rejection developed post-transplantation lymphoproliferative disorders [148 ]. 

Nervous system Demyelinating disorders provoked by mAbs are said to affect 0.02-0.2% of treated patients. Three patients with chronic lymphocytic anaemia developed acute inflammatory demyelinating neuropathy while being treated with alemtuzumab [90 ]. All three showed a good clinical response to treatment with intravenous immunoglobulin. 

---